Loading
A phase 2 trial of JNJ-79635322 in multiple myeloma, run by Janssen Research & Development, LLC, now recruiting.
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT07266441 by Janssen Research & Development, LLC, with 157 participants planned, started 2026-02-08 and due to reach its primary completion in 2027-06-14. Interventions recorded: JNJ-79635322. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares JNJ-79635322, Relapsed or refractory multiple myeloma, Johnson & Johnson, Multiple myeloma.
Shares JNJ-79635322, Relapsed or refractory multiple myeloma, Johnson & Johnson, Multiple myeloma.
Shares JNJ-79635322, Relapsed or refractory multiple myeloma, Johnson & Johnson, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Johnson & Johnson, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.